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Prosthetic implants are frequently used for breast augmentation and breast reconstruction following mastectomy. Unfortunately,
long-term aesthetic results of prosthetic breast restorationmay be hindered by complications such as rippling, capsular contracture,
and implant malposition. The advent of use of acellular dermal matrices has greatly improved the outcomes of prosthetic breast
reconstruction. We describe a case of rippling deformity of breast that was treated using an acellular dermal matrix product,
AlloMax. The patient presented with visible rippling of bilateral prosthetic breast implants as well as significant asymmetry of
the breasts after multiple excisional biopsies for right breast ductal carcinoma in situ. A 6 × 10 cm piece of AlloMax was placed on
the medial aspect of each breast between the implant and the skin flap. Follow-up was performed at 1 week, 3 months, and 1 year
following the procedure. The patient recovered well from the surgery and there were no complications. At her first postoperative
follow-up the patient was extremely satisfied with the result. At her 3-month and 1-year follow-up she had no recurrence of her
previous deformity and no new deformity.
1. Introduction
Prosthetic implant use for cosmetic breast augmentation and
postmastectomy breast reconstruction is a common proce-
dure. Unfortunately, there are several long-term complica-
tions of breast restoration with prosthetic implants, such as
rippling, capsular contracture, implant malposition, bottom-
ing out, implant exposure, and symmastia. Amajority of these
complications are due to thinning of the overlying skin as a
result of expansion process, periprosthetic atrophy, formation
of a thin or atrophic capsule, inadequate filling or incorrect
placement of the implant, or overgenerous formation of the
breast pocket [1, 2]. Rippling is the appearance of vertical folds
on the skin of a patient with a prosthetic breast implant and is
most visible when the patient is in an upright and/or forward-
leaning position. It is noted in about 0–10% of patients after
prosthetic breast implant augmentation/reconstruction [3–5]
and 5–50% of cases require reoperation [4].
Rippling and other aesthetic complications related with
breast implants have been very difficult to manage with
revisionary surgery. High recurrence rates and low patient
satisfaction are frequent. However, reconstructive surgeons
achieved greatly improved outcomes since the advent of use
of acellular dermal matrix (ADM) [3, 4]. ADM adds an
extra layer of tissue between the implant and the skin and
therefore decreases the visibility of implant. A review of
the current literature includes many references to the use
of AlloDerm (Life-Cell Corporation, Branchburg, NJ), the
first commercially available ADM product, to repair breast
rippling associated with prosthetic implants [5–7] but there
is currently no literature on the use of AlloMax (Bard-Davol,
Warwick, RI) for the same indication. AlloMax is a similar
ADM product; however, in contrast to AlloDerm, AlloMax
is terminally sterilized using Tutoplast process, which is a
proprietary process for decellularization, sterilization, and
viral inactivation.
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Figure 1: Preoperatively IMFs of the patient were asymmetric (a) and rippling was noticeable in the medial aspects of her breasts ((b) and
(c)). Postoperatively IMFs were at the same level (d) and rippling deformity disappeared ((e) and (f)).
Herein, we describe a case in which we have treated the
bilateral breast rippling deformity of a patient using AlloMax.
2. Case Report
The patient was a 47-year-old woman who presented with
visible rippling of bilateral prosthetic breast implants after
multiple excisional biopsies for right breast ductal carci-
noma in situ (DCIS). She had placement of bilateral saline
prosthetic implants for cosmetic breast augmentation from
a negative A to a C in 2000 with good results and no
immediate postoperative complications. She was diagnosed
with DCIS of the right breast in 2012 and underwent wire-
guided excisional biopsy of the right inferolateral quadrant
with subsequent reexcision for positive margins. Following
these procedures, she noted significant breast asymmetry and
rippling deformity in both of her breasts. On admission, she
had asymmetric breasts with a well-healed horizontal scar on
her right breast 1-2 cm above the inframammary fold (IMF).
The IMF to nipple distance was significantly decreased on the
right side compared to the left side and right nipple was more
ptotic (Figure 1(a)). Rippling was visible along the medial
borders of the breasts bilaterally (Figures 1(b) and 1(c)).
Because of the patient’s thin skin we decided to proceed
with right breast augmentation with the exchange of implant
to a larger size implant (275 to 350mL) and placement of
AlloMax bilaterally to improve the rippling. In the operating
room, attention was first turned to the right breast, where
a hypertrophic scar from previous biopsy site was noted
(Figure 2(a)).Wemade an incision to excise the hypertrophic
scar, and incision was carried down to the subcutaneous
fascia through the capsule. We opened the capsule and
removed the existing 275 cc normal saline implant (Mentor,
Santa Barbara, CA).We also performed amedial and superior
capsulectomy. For reconstruction, we soaked a 6 × 20 cm
AlloMaxdermalmatrix sheath in normal saline for 5minutes.
The thickness of AlloMax was between 0.8 and 1.8mm. We
cut it into half and placed a 6 × 10 cm segment on the
medial aspect of the left breast between the implant and
the skin flap. The distal aspect remained free to prevent
tethering. We replaced the original implant with a smooth,
round, and moderate profile and 300 cc saline breast implant
with a diaphragm valve (Mentor, Santa Barbara, CA). We
expanded the implant to a 350 cc total volume, approximately
75 cc above the original implant, and closed the incision in
layers. Attention was then turned to the left breast where
we opened the capsule and removed the existing implant
intact. We performed a capsulectomy on medial aspect and
placed the other half of AlloMax, measuring approximately
6 × 10 cm, between the implant and the skin flap. We secured
theAlloMax proximally to the chest wall using 4-0 absorbable
suture in interrupted fashion. After irrigation, we placed
the implant back into the pocket and closed the wound in
layers (Figure 2(b)). The patient was discharged from the
postanesthesia care unit the same day with no apparent
complications.
The patient returned for a postoperative follow-up visit 5
days following her procedure. There were no wound related
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Figure 2:The picture shows the level of discrepancy between the IMFs on the left and right breasts (a) before the operation and the immediate
postoperative results following the wound closure.
Table 1: The key differences between AlloDerm and AlloMax (adapted from [8]).
Product Source Prep. time Preparation Refrigeration Sterility Orientation Cross-linking Shelflife Cost/cm
2
AlloDerm Human 10–40min
2 baths of warm NS1 or
LR2; the second should
include antibiotics
No No Yes No 2 y $28
AlloMax Human 3min Room temp. NS No Yes No No 5 y $32.38
1NS: normal saline; 2LR: Lactated Ringer’s.
complications. At 3-month follow-up the incisions were well-
healed with no hypertrophic scaring. There was no recur-
rence of rippling and IMFs were symmetric bilaterally. At
1-year follow-up patient’s breasts were symmetric bilaterally
with no visible rippling of the medial or inferolateral edge
of either breast (Figures 1(d), 1(e), and 1(f)). The patient was
satisfied with the overall result.
3. Discussion
The use of ADM as a filler for correction of implant-related
breast deformity has been commonplace for many years [3,
6]. Revisionary procedures performed using ADM improved
the appearance of rippling in 85% of the patients [6] with
failure rates as low as 5% [9]. ADM is placed by either capsular
onlay or lower pole suspension technique to revise rippling
deformity. In the dermal onlay technique, the implant is
removed and placed in antibiotic solution. The ADM is then
sutured into place between the capsule and the implant, same
as the technique we have used in this case. The lower pole
suspension technique is very similar to placement of anADM
sling in primary procedures: the ADM is sutured to the IMF
and the inferior border of the pectoralis major muscle to
support the inferior aspect of the implant. This elevates the
prosthetic implant and ameliorates underfilling of the upper
pole.
Themost extensively studiedADM isAlloDerm, a human
cadaveric split thickness dermis manufactured by Life-Cell
Corporation. AlloDerm is referenced in 572 articles in the
PubMed Database, 77 of which describe its use in breast
reconstruction. AlloMax, an acellular human dermal graft
that is described by the manufacturer as “acellular dermal
collagen,” is similar to AlloDerm. However AlloMax is pre-
pared using a unique process named Tutoplast process, first
invented by Tutogen (later merged with RTI Biologics Inc.,
Alachua, FL), which is a proprietary process for decellulariza-
tion, sterilization, and viral inactivation of the graft material
[10, 11]. The Tutoplast process is a five-step procedure that
results in terminal sterilization of the product, and currently
AlloMax is one of the two terminally sterilizedADMs that are
commercially available [12].
There are other subtle differences between AlloDerm and
AlloMax as noted by the manufacturer. Some of the key
benefits of AlloMax as compared to AlloDerm are the shorter
preparation time, terminal sterility, and the fact that no
orientation is necessary for implantation [13] (Table 1). Also
because the Tutoplast process negates the need for antibiotic
soaking prior to implantation there are no allergenic con-
traindications to implantation at this time. Although the cost
per cm2 for AlloMax is slightly higher than for AlloDerm,
there are certain cost saving measures built into its use, such
as the reduction in preparation time, single hydration step,
and longer shelf life. Additionally, AlloDerm was associated
with increased incidence of postoperative wound infections
after breast reconstruction, and it is the main etiologic factor
behind a sterile, chronic cellulitis known as “red breast syn-
drome” [8, 14, 15]. The syndrome resolves without treatment
but results in clinical confusion and patient discomfort.
There are no reports relating the occurrence of “red breast
syndrome” with AlloMax. Despite all the advantages, it is still
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controversial if the integration of AlloMax to the recipient
bed is impeded by the Tutoplast processes [12].
A terminally sterilized form of AlloDerm (RTU (ready
to use) AlloDerm) has been introduced and utilized recently
to address the issues related with the use of aseptic (non-
sterile) AlloDerm [16, 17]. Overall infection rates in patients
undergoing reconstruction with RTU AlloDerm decreased
significantly. However, as in case of AlloMax, the effect of the
terminal sterilization procedure on the incorporation of the
RTU AlloDerm to the recipient tissues remains controversial
[16].
The other ADM products that can be used in breast
reconstruction are Strattice, DermaMatrix, SurgiMend, Ver-
itas, and FlexHD. Among these only the DermaMatrix and
Flex HD are human origin ADMs. Strattice, SurgiMend, and
Veritas are obtained from various animal resources which can
be considered as a drawback in their clinical use. Strattice
and FlexHD are mostly used for breast reconstruction while
the other products are generally used for the reconstruction
of other deformities, such as abdominal hernia. Strattice
is obtained from porcine skin which is less desirable than
human skin but on the other hand it is thicker and stronger
than AlloDerm and it is a terminally sterile product that
is available in larger pieces (up to 20 × 25 cm), potentially
minimizing wound dehiscence. FlexHD is described as acel-
lular hydrated dermis and is derived from cadaveric human
allograft skin. It is delivered prehydrated and does not require
refrigeration; furthermore, it exhibits resistance to stretch and
biomechanical strength resulting in a tissue graft that is ready
for immediate use, potentially reducing operation room time
[18].
Another alternative for the treatment for the rippling
deformity of breast that should be discussed is fat grafting.
Ease of fat harvest and abundance of donor sites in addition
to the discovery of vasculogenic stem cells within adipose
tissue increased the popularity of fat grafting in the last
decade. The major drawbacks of the fat grafting, however,
are cyst formation and benign calcifications in the breast
that may obscure the diagnosis of future malignant lesions.
Therefore, the patients should be selected carefully and if
possible fat grafting should be avoided in patientswith history
or increased risk of breast cancer such as the patient in this
case report.
The correct use and placement of an ADM are imperative
when using the material for breast reconstruction or other
indications.The learning curve can be quite high and includes
attention to such aspects as proper rehydration of the mate-
rial, proper fit, and elimination of dead space around and
within the material [4]. AlloMax has specific use instructions
that may differ in some respects from other ADMs so it
is important to get familiarized with the material before
proceeding with clinical application.
4. Conclusion
This single patient case report demonstrates good aesthetic
outcome up to 1 year after the operation with the use of
AlloMax to correct breast rippling deformity. Our group is
currently enrolling patients for a randomized controlled trial
to compare the infection rates between the breast reconstruc-
tion cases performed by using AlloMax or AlloDerm.Wewill
also observe the tissue incorporation of the two materials in
order to offer a solution to the ongoing controversy on this
topic.
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